ANDA 62676, held by Sun Pharmaceutical Industries. Doxycycline Hyclate.
As of Nov 21, 2026, ANDA 62676 (Doxycycline Hyclate), held by Sun Pharmaceutical Industries, was first approved by FDA on Jul 10, 1986, with 30 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 10, 1986 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 100MG BASE · capsule;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 50MG BASE · capsule;oral | Doxycycline Hyclate | Rx |
| Apr 1, 2025 | Supplement 57Labeling · Standard review | Approved | None posted |
| May 17, 2021 | Supplement 53Labeling · Standard review | Approved | None posted |
| May 17, 2021 | Supplement 51Labeling · Standard review | Approved | None posted |
| May 15, 2018 | Supplement 50Labeling · Standard review | Approved | None posted |
| May 15, 2018 | Supplement 49Labeling · Standard review | Approved | None posted |
| May 15, 2018 | Supplement 47Labeling · Standard review | Approved | None posted |
| May 15, 2018 | Supplement 46Labeling · Standard review | Approved | None posted |
| Sep 10, 2015 | Supplement 42Labeling · Standard review | Approved | None posted |
| Jul 24, 2013 | Supplement 40Labeling · Standard review | Approved | None posted |
| Nov 30, 2011 | Supplement 37Labeling | Approved | None posted |
| May 29, 2008 | Supplement 33Labeling | Approved | None posted |
| Sep 28, 2006 | Supplement 31Labeling | Approved | None posted |
| Mar 8, 2006 | Supplement 27Labeling | Approved | None posted |
| Jul 6, 2005 | Supplement 23Labeling | Approved | None posted |
| Apr 1, 2003 | Supplement 20Labeling | Approved | None posted |
| Feb 26, 2002 | Supplement 16Labeling | Approved | None posted |
| Apr 12, 2001 | Supplement 15Manufacturing | Approved | None posted |
| May 16, 2000 | Supplement 14Manufacturing | Approved | None posted |
| May 16, 2000 | Supplement 13Manufacturing | Approved | None posted |
| Jul 20, 1999 | Supplement 12Manufacturing | Approved | None posted |
| Jul 20, 1999 | Supplement 11Manufacturing | Approved | None posted |
| Dec 5, 1997 | Supplement 10Manufacturing | Approved | None posted |
| Apr 21, 1997 | Supplement 8Manufacturing | Approved | None posted |
| Feb 24, 1997 | Supplement 9Manufacturing | Approved | None posted |
| Jan 12, 1994 | Supplement 7Manufacturing | Approved | None posted |
| Jul 6, 1993 | Supplement 6Labeling | Approved | None posted |
| Mar 26, 1993 | Supplement 5Labeling | Approved | None posted |
| Jan 12, 1993 | Supplement 4Labeling | Approved | None posted |
| Mar 16, 1992 | Supplement 3Labeling | Approved | None posted |
| May 1, 1989 | Supplement 1Manufacturing | Approved | None posted |
| Jul 10, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters